BRAF and neoplasm: The average reduction in tumor size was 91%, and progression-free survival (PFS) was 87% at 12 months (95% CI, 57 to 98) and 58% at 24 months.338 Numerous ongoing studies are currently underway, with participants either receiving intervention or undergoing examination to assess the clinical and pathological responses to Vemurafenib and Cobimetinib in BRAF-positive cancers (NCT05768178, NCT02036086).